Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14872561 | 1.00 | DHFR (0.71) | DHFRSLC2A1 | |
| SCHEMBL14870312 | 0.83 | DHFR (0.77) | DHFRSLC2A1 | |
| SCHEMBL8635467 | 0.81 | DHFR (1.00) | DHFRSLC2A1 | |
| SCHEMBL29579939 | 0.81 | DHFR (1.00) | DHFRSLC2A1 | |
| SCHEMBL8934057 | 0.73 | DHFR (0.79) | DHFRSLC2A1 | |
| Bromide SCHEMBL9396234 | 0.73 | DHFR (0.66) | DHFRSLC2A1 | |
| SCHEMBL13545909 | 0.72 | PPARA (0.59) | — | |
| Hydrochloric Acid SCHEMBL3146300 | 0.72 | PPARA (0.53) | — | |
| Bromide SCHEMBL8934281 | 0.72 | DHFR (0.78) | DHFRSLC2A1 | |
| SCHEMBL8934103 | 0.72 | SLC2A1 (0.71) | DHFRSLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11964944-B2 | Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases | THE UNIVERSITY OF CHICAGO (US) | 2024-04-23 | — | — | US | disclosed |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230140413-A1 | Compounds and Methods for Treating, Detecting, and Identifying Compounds to Treat Apicomplexan Parasitic Diseases | THE UNIVERSITY OF CHICAGO | 2023-05-04 | — | — | US | disclosed |
| US-11414385-B2 | Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases | THE UNIVERSITY OF CHICAGO | 2022-08-16 | — | — | US | disclosed |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11964944-B2 | Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases | TUBB1, MYADM, TUBB | DHFR 71/4885SLC2A1 4114/4885 |
| US-20230140413-A1 | Compounds and Methods for Treating, Detecting, and Identifying Compounds to Treat Apicomplexan Parasitic Diseases | TUBB1, MYADM, TUBB | DHFR 71/4885SLC2A1 4114/4885 |
| US-11414385-B2 | Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases | TUBB1, MYADM, TUBB | DHFR 70/4885SLC2A1 4082/4885 |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | DHFR 1080/4885SLC2A1 22/4885 |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | SLC5A2, SLC5A1, GPR119 | DHFR 1080/4885SLC2A1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.